Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2012

Distribution Deal for Maine’s Fast Protein Array Portfolio

  • Scienion has been appointed nonexclusive worldwide distributor for the complete line of Maine Manufacturing’s nitrocellulose-coated Fast® protein array products. The line also includes the Fast Quanto micro ELISA arrays with specific cytokine antibody panels, and the Serum Biomarker Chip, a rante of multiplexed immunoassays for measuring key cellular growth proteins, together wtih accessories and comsumables.

    Scienion offers systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceuticals, and other applications, including microarray-based analytics. The firm says Maine’s Fast slide portfolio will ideally complement its existing hardware business.

    “Scienion, with its cutting-edge non-contact printing technology, is a well-recognized solution provider of lab automation and miniaturization in life sciences,” notes Bill Emhiser, Maine’s president. Maine Manufacturing provides expertise in membranes and surface chemistries. “Our collaboration provides our customers a complete solution for protein analysis.” 

    Maine Manufacturing provides expertise in membranes and surface chemistries.

    Contract manufacturer Maine is focused on focus on specialty plastic, filtration, membrane and fluid technologies for a range of life science applications, and offers research and development, prototyping, low- to high-volume production, and assembly services.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »